Reducing the transcriptional read‐through rate of a lentiviral vector for β ‐thalassemia gene therapy
The Journal of Gene Medicine · 2024
DOI: 10.1002/jgm.3640 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Jiahui Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: beta-Thalassemia. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Novo Nordisk Haemophilia Research Fund in China, National Key Research and Development Program of China, Youth Project of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Background
LentiGlobin BB305 is a self‐inactivating lentiviral vector carrying a human β ‐globin expressing cassette for treating β ‐thalassemia. Initially, a 2 × 250 bp chicken Locus Control Region fragment of cHS4, functioning as an insulator, was placed at its ΔU3, which was removed after the first clinical trial led by a French team to avoid abnormal splicing, etc. This action could potentially lead to an increasing risk of the transcriptional read‐through rate driven by the β ‐globin promoter to a significant level, posing a biosafety risk in clinical trials.
Methods
In the present study, a read‐through reducing agent (C‐U+ or WPRE) was designed to be placed at the 3′ UTR of the β ‐globin gene. The Enhancer Activities and/or Transcriptional Read‐Through (EATRT) rate at the mRNA level and the protein expression level regarding lentiviral preparation titer were examined.
Results
We found that the insertion of the element (C‐U+ or WPRE) reduced the EATRT effectively by 53% or 41%, respectively. C‐U+ has less impact on virus package efficiency. Furthermore, there was no significant difference in the protein expression level after the C‐U+ or WPRE insertion.
Conclusions
The results of the present study show that inserting C‐U+ or WPRE before the polyA sequence of the BB305 would reduce the EATRT rate at no cost of its expressing efficacy and viral preparation titers. Thus, we present an alternative improvement for a safer lentiviral vector for β ‐thalassemia clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- NHC Key Laboratory of Medical Embryogenesis and Developmental Molecular Biology & Shanghai Key Laboratory of Embryo and Reproduction Engineering, Shanghai, China.
- Department of Histo-Embryology, Genetics and Developmental Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- School of Pharmacy, Macau University of Science and Technology, Macau, China.
Förderung
- Novo Nordisk Haemophilia Research Fund in China
- National Key Research and Development Program of China
- Youth Project of Shanghai Municipal Health Commission
- Medical-Engineering Cross Project of Shanghai Jiao Tong University
- National Natural Science Foundation for Youth Cultivation Project of Shanghai Children's Hospital
- National Natural Science Foundation of China
- Shanghai Key Clinical Specialty Proiect
- Shanghai Top Priority Key Discipline Project
Zitieren
APA
Wu, J., Chen, Y., Shen, W., Zhang, J., & Zeng, F. (2024). Reducing the transcriptional read‐through rate of a lentiviral vector for β ‐thalassemia gene therapy. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3640
Vancouver
Wu J, Chen Y, Shen W, Zhang J, Zeng F. Reducing the transcriptional read‐through rate of a lentiviral vector for β ‐thalassemia gene therapy. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3640
BibTeX
@article{Wu2024,
author = {Wu, Jiahui and Chen, Yuan and Shen, Wenchen and Zhang, Jingzhi and Zeng, Fanyi},
title = {Reducing the transcriptional read‐through rate of a lentiviral vector for β ‐thalassemia gene therapy},
journal = {The Journal of Gene Medicine},
year = {2024},
doi = {10.1002/jgm.3640}
}
EUVIMED